NFKB1 and ovarian carcinoma: Moreover, pterostilbene decreased the release of TNF-α cytokines in IGROV-1 cells by inhibiting the NF-κB, AKT, and ERK pathways and helped to reduce the effect activity and translocation of NF-κB in the treatment of ovarian cancer [133].